Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 3
1(25.0%)
4Total
Phase 2(3)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05914194Phase 3Not Yet Recruiting

A Eight-Week Study of NLS-2 (Mazindol Extended Release) in Participants With Narcolepsy Type 1

Role: lead

NCT05055024Phase 2Completed

An Open Label Study of NLS-2 (Mazindol Extended Release) in Subjects With Narcolepsy

Role: lead

NCT04923594Phase 2Completed

Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of Narcolepsy

Role: lead

NCT02808104Phase 2Completed

Mazindol Controlled Release in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Role: lead

All 4 trials loaded